Browsing tag:

acute myeloid leukemia


Boehringer Ingelheim recently shared exciting Phase II results from their anti-cancer breakthrough drug Volasertib. Patients enrolled in this landmark study, revealed July 8, 2014, had acute myeloid leukemia, or AML, and were considered to have unresectable cases. The study encompassed an elderly patient population, with every participant being over the age of 65. Results have[…]

Read More

Exciting news was revealed on June 18, 2014 with the announcement the Mocetinostat Orphan Drug Designation from the FDA. Information gleaned from a Phase 1/2 study of Mocetinostat showed that when used alongside Azacitidine (Vidaza) this combination provided efficacious treatment for patients with myelodysplastic syndromes. Patients who were at intermediate or high risk myelodysplastic syndromes,[…]

Read More

On September 17, 2013 the FDA announced that Breakthrough Status was awarded to Volasertib. Currently marketed by Boehringer Ingelheim, this Volasertib breakthrough designation by the FDA is encouraging for patients suffering from acute myeloid leukemia. Volasertib is unique as it is a selective and powerful polo-like kinase inhibitor. Although Volasertib is currently an unapproved and[…]

Read More

Over the past decade, pharmaceutical firms have been giving oncologists the choice to combine several drugs used in cancer treatment in order to battle even the most resistant of cancer cells. This move has been proven successful in some types of cancer, prompting pharmaceutical manufacturers to supply consistent, quality-controlled active pharmaceutical ingredients (API’s), such as[…]

Read More

This website uses cookies. By using our site, you agree to our terms of service